Retatrutide vs Mounjaro: Which Weight Loss Medication to Choose

Ghanaian patients now have access to both Mounjaro (tirzepatide) and retatrutide through medical weight loss services. Both represent significant advances over first-generation medications, but they work differently. This comparison helps you understand which might better suit your situation.

The Fundamental Difference

Mounjaro activates two receptors (GLP-1 and GIP), while retatrutide activates three (GLP-1, GIP, and glucagon). This isn't just marketing—the additional receptor creates a measurably different effect on your body's metabolism.

Think of it this way: Mounjaro primarily reduces how much you want to eat and improves how your body processes nutrients. Retatrutide does both of these things plus actively increases how many calories your body burns throughout the day.

Weight Loss Results Compared

Mounjaro (Tirzepatide) Trial Data

Published clinical trials established tirzepatide as the most effective weight loss medication at the time of its approval. Participants achieved:

• Significant weight loss at the highest dose
• Maximum individual results exceeding 25% in some participants
• 91% of patients lost at least 5% body weight
• 57% lost at least 20% body weight

Retatrutide Trial Data

Phase 2 trials for retatrutide showed even higher numbers:

• Average weight loss of 24.2% at the 12mg dose
• 17.5% weight loss even at lower doses
• 91% achieved at least 5% weight loss
• 63% lost at least 20% body weight

The approximately 3-4 percentage point difference between the medications translates to meaningful additional weight loss for many patients. For someone weighing 100kg, this could mean an extra 3-4kg lost.

How They Make You Feel

Appetite Effects

Both medications substantially reduce appetite and food cravings. Patients on either report feeling satisfied with smaller portions, reduced interest in snacking, and diminished food noise—the constant background thoughts about eating.

The appetite suppression mechanism is similar between medications, as both activate GLP-1 and GIP receptors. Most patients cannot distinguish between them based on appetite effects alone.

Energy and Metabolism

This is where differences emerge. Retatrutide's glucagon activation increases basal metabolic rate—the energy your body burns at rest. Some patients report feeling more energetic, though this varies individually.

Mounjaro doesn't provide this metabolic boost. Weight loss comes primarily from reduced caloric intake rather than increased expenditure.

Side Effect Profiles

Both medications share common GLP-1 side effects, particularly during dose escalation:

• Nausea (most common, usually temporary)
• Decreased appetite (the intended effect)
• Gastrointestinal discomfort
• Constipation or diarrhea
• Fatigue during adjustment

Retatrutide's glucagon component may produce slightly different effects in some individuals. The full side effect profile will become clearer as Phase 3 trial data emerges and more patients receive treatment.

Regulatory Status

Mounjaro

Tirzepatide is approved for type 2 diabetes (as Mounjaro®, 2022) and weight loss (as Zepbound®, 2023). Extensive real-world data now exists from millions of patients globally. The safety profile is well-established.

Retatrutide

Currently in Phase 3 clinical trials. Not yet approved by regulatory agencies. Available in Ghana through compounded formulations under medical supervision. Less real-world data exists, though Phase 2 trials showed an acceptable safety profile.

Practical Considerations for Ghanaian Patients

Availability

Both medications are available through medical weight loss services in Accra, Kumasi, and other Ghanaian cities. Brand-name Mounjaro is not distributed through standard Ghana pharmacy channels; compounded versions are typically provided.

Storage Requirements

Both require refrigeration between 2-8°C. In Ghana's climate, this means keeping medication in your refrigerator and ensuring cold-chain delivery. Our service handles temperature-controlled transport.

Dosing Schedule

Both are weekly injections. The convenience factor is identical—one brief injection per week regardless of which medication you choose.

Who Should Choose Mounjaro?

• Patients who prefer a fully-approved medication with extensive safety data
• Those with type 2 diabetes who want combined diabetes and weight management
• Individuals comfortable with 20%+ weight loss as the goal
• Patients who have successfully used other GLP-1 medications and want to step up

Who Should Choose Retatrutide?

• Patients seeking maximum possible weight loss
• Those interested in the metabolic boost from glucagon activation
• Individuals who have plateaued on tirzepatide and want to try the next generation
• Patients comfortable with a newer medication under medical supervision

Making Your Decision

Both medications represent substantial advances in weight loss treatment. The choice between them depends on your individual priorities—whether you value the established track record of tirzepatide or the potentially superior results of retatrutide. A consultation with our medical team can help clarify which option aligns with your health situation and goals.